Antitumoral Activity and Metabolic Signatures of Dichloroacetate, 6-Aminonicotinamide and Etomoxir in Breast-Tumor-Educated Macrophages

abstract

Pharmacological targeting of metabolic pathways represents an appealing strategy to selectively kill cancer cells while promoting antitumor functions of stromal cells. In this study, we assessed the effectiveness of 13 metabolic drugs (MDs) in steering in vitro generated breast tumor-educated macrophages (TEMs) toward an antitumoral phenotype. For that, the production of vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-alpha), two important regulators of tumor progression, was evaluated. Notably, dichloroacetate (DCA), 6-aminonicotinamide (6-AN), and etomoxir decreased VEGF production and enhanced TNF-alpha release. Hence, we further clarified their impact on TEM metabolism using an untargeted NMR-based metabolomics approach. DCA downregulated glycolysis and enhanced the utilization of extracellular substrates like lactate while reconfiguring lipid metabolism. Several DCA-induced changes significantly correlated with heightened TNF-alpha production in response to pro-inflammatory stimulation. The inhibition of the pentose phosphate pathway by 6-AN was accompanied by enhanced glutaminolysis, which correlated with a decreased level of VEGF production. In etomoxir-treated TEM, inhibition of fatty acid oxidation was compensated through upregulation of glycolysis, catabolism of intracellular amino acids, and consumption of extracellular branched chain alpha-ketoacids (BCKA) and citrate. Overall, our results offer a comprehensive view of the metabolic signature of each MD in breast TEM and highlight putative correlations with phenotypic effects.

keywords

FATTY-ACID OXIDATION; NITRIC-OXIDE; INHIBITION; RESISTANCE; GROWTH; CELLS; M2

subject category

Biochemistry & Molecular Biology

authors

Dias, AS; Almeida, CR; Helguero, L; Duarte, IF

our authors

acknowledgements

This work was developed within the scope of the projects iBiMED-Institute of Biomedicine (UIDB/04501/2020 and UIDP/04501/2020) and CICECO-Aveiro Institute of Materials UIDB/50011/2020 (DOI 10.54499/UIDB/50011/2020), UIDP/50011/2020 (DOI 10.54499/UIDP/50011/2020), and LA/P/0006/2020 (DOI 10.54499/LA/P/0006/2020), financed by national funds through the FCT/MEC (PIDDAC). FCT is acknowledged for the individual grant to A.S.D. (SFRH/BD/140322/2018) and the research contract under the Scientific Employment Stimulus to I.F.D. (CEECIND/02387/2018). The NMR spectrometer is part of the National NMR Network (PTNMR), partially supported by Infrastructure Project No. 022161 (cofinanced by FEDER through COMPETE2020, POCI, and PORL and FCT through PIDDAC).

Share this project:

Related Publications

We use cookies for marketing activities and to offer you a better experience. By clicking “Accept Cookies” you agree with our cookie policy. Read about how we use cookies by clicking "Privacy and Cookie Policy".